Go6976

NMDA (CAT No: HB0454) and XE-991 (M channel/Kv7 blocker, CAT No: HB1090) were purchased from Hellobio (Princeton, NJ, USA) and were dissolved in water to make a stock solution. They were delivered into the recording chamber at their final concentrations through a syringe pump. PKC activator, PMA (CAT No: ab120297) and PKC inhibitor, GF 109203X (Bisindolylmaleimide 1 (Bis-1), CAT No: ab120844) were purchased from Abcam (Cambridge, UK) and were dissolved in DMSO to make a stock solution. They were added to the incubation solution at a concentration of 1.0 μM for PMA and 2.5 μM for Bis-1. The following agents were dissolved in DMSO to make a stock solution and were added to the internal solution. CaM antagonist, W-7 (CAT No: ab143768) was obtained from Abcam, and PIP2 (CAT No: P-4508-2) was purchased from Echelon Bioscience (Salt Lake City, UT, USA). LY294002 (CAT No: HY-10108, PI3K inhibitor) and AS605240 (CAT No: HY-10109, a specific inhibitor of the PI3Kγ) were purchased from MCE (Monmouth Junction, NJ, USA). Go6976 (CAT No: ab141413, a specific inhibitor of PKCα and PKCβ) and LY333531 (CAT No: ab219866, selective PKCβ inhibitor) were purchased from Abcam.

Bryostatin analogs (1–3) were synthesized as described before [11 (link),12 (link),14 (link)]. T-705 was obtained from Boc Sciences (New York, USA). Go 6976 was purchased from Abcam Biochemicals (Cambridge, UK) and sotrastaurin from Axon Medchem BV (The Netherlands). All compounds were dissolved in analytical grade DMSO to yield 10 mg/ml stocks. The compounds were protected from light and were stored at −20°C until used. Arbidol was a kind gift by Prof. S. Polyak (University of Washington, Seattle, USA) and was dissolved as a 10 mg/ml solution in 100% ethanol after which it was 10-fold diluted with sterile water before use.